Abstract: FR-PO1123
Impact of Treating Metabolic Acidosis in CKD: Consideration of Time-Varying Confounding among Treatment, Kidney Function, and Acidosis through G-formula
Session Information
- CKD: Epidemiology, Risk Factors, and Prevention - 2
October 25, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Kwon, Soie, Chung Ang University Hospital, Seoul, Korea (the Republic of)
- Lee, Jung Pyo, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Dongjak-gu, Seoul, Korea (the Republic of)
Background
The debate on whether treating metabolic acidosis decelerates CKD progression persists despite extensive research. Bicarbonate therapy mitigates metabolic acidosis, yet CKD exacerbates it, highlighting the necessity to examine these interactions comprehensively. This study employs G-formula to assess the impact of metabolic acidosis treatment in CKD, considering those intricate interactions.
Methods
A retrospective cohort study was conducted on patients whose eGFR of less than 60 was confirmed at 3-month intervals in two tertiary referral centers. Time-varying Cox analysis and G-formula were used to consider the time-varying effect of metabolic acidosis. In particular, the G-formula was adopted to account for the time-varying confounding between bicarbonate medication, serum total CO2, and creatinine level.
Results
The study included 19,627 participants over a median follow-up of 12 years. 4,127 patients advanced to ESKD and 6,273 patients died. Previous serum TCO2 levels (Coefficient 0.163, 95% CI 0.140–0.186) and bicarbonate treatment (0.898,0.897–0.899) positively influenced the following visit's serum TCO2, whereas previous serum creatinine (-0.398, -0.406– -0.391, <0.001) showed a negative correlation. Time-varying Cox analysis suggested metabolic acidosis treatment heightened risks of ESKD progression (aHR 4.28, 95% CI 3.950–4.637) and mortality (aHR 1.22, 95% CI 1.096–1.353). However, implementing the G-formula revealed treatment significantly reduced ESKD progression (aHR 0.90, 95% CI 0.874–0.927) and mortality rates (aHR 0.94, 95% CI 0.934–0.950). Determining the optimal TCO2 levels for bicarbonate administration, we found that <22 offered the most considerable risk reduction (Table 1).
Conclusion
Properly addressing the time-varying confounding among bicarbonate treatment, metabolic acidosis, and renal function suggests the potential benefit of metabolic acidosis treatment in lowering the rates of ESKD progression and mortality among CKD patients.